News

October 19, 2018

Soligenix Extends Enrollment in Phase 3 Trial of SGX301 in Cutaneous T-cell Lymphoma

News

The pivotal Phase 3 trial testing Soligenix‘s SGX301 will recruit an additional 40 subjects with cutaneous T-cell lymphoma — a kind of lymphoma of the skin — after a positive recommendation from an ... Read more

October 18, 2018

MEI Pharma, BeiGene Will Evaluate New Combo Therapy for B-cell Cancers

News

A recent collaboration between MEI Pharma and BeiGene will test a combination of two investigational cancer therapies, ME-401 and zanubrutinib, for treating patients with B-cell cancers. Under the new partnership, MEI Pharma will amend its ongoing ... Read more

October 17, 2018

AFM11 Clinical Program for Lymphoma and Leukemia on Hold Over Safety Concerns

News

Affimed has placed its AFM11 Phase 1 program on clinical hold after two life-threatening events in its lymphoma trial and one death in the leukemia study, the company announced in a press release. ... Read more

October 16, 2018

Publication of Phase 3 Trial Results Supports FDA Approval of Copiktra, Verastem Announces

News

Copiktra (duvelisib) monotherapy may be an effective and safe treatment option for patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to results from a Phase 3 ... Read more

October 15, 2018

FDA Committee Recommends Truxima’s Approval for 3 Non-Hodgkin’s Lymphoma Indications

News

Truxima (CT-P10) a biosimilar to Rituxan (rituximab), has been unanimously recommended for approval by the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee for the treatment of three non-Hodgkin’s lymphoma (NHL) indications, ... Read more

October 12, 2018

Axicabtagene Ciloleucel Gets Japan’s Orphan Drug Designation to Treat Some Non-Hodgkin’s Lymphomas

News

The Japan Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug status to axicabtagene ciloleucel for the treatment of certain aggressive forms of non-Hodgkin’s lymphoma (NHL) namely diffuse large ... Read more

October 11, 2018

Beigene’s Lymphoma Treatment Zanubrutinib Shows High Response Rates in Chinese Phase 1 Trial

News

BeiGene‘s investigational zanubrutinib is showing promising response rates, ranging from 42% to 100%, in several B-cell lymphoma subtypes, preliminary data from a Chinese Phase 1 trial show. Treatment was also well-tolerated. Jun ... Read more

October 10, 2018October 10, 2018

9 in 10 Heavily Treated CTCL Patients See Benefits with IPH4102, Phase 1 Trial Shows

News

IPH4102, Innate Pharma’s investigational antibody, reduced tumor volume in 36% of patients with cutaneous T-cell lymphoma (CTCL) in a Phase 1 trial. Patients were heavily pre-treated, having received at least two ... Read more

October 9, 2018October 9, 2018

LLS Seeks Corporate Support for Annual ‘Light The Night’ Campaign

News

The Leukemia & Lymphoma Society (LLS) says there’s still time to join its annual Light The Night fundraising campaign, which aims to help blood cancer patients nationwide and illuminate paths to ... Read more

October 8, 2018

Portola’s Cerdulatinib Wins Orphan Drug Designation for Peripheral T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Portola Pharmaceuticals‘ investigative therapy cerdulatinib to treat patients with peripheral T-cell lymphoma (PTCL), the company announced. Orphan drug designation aims to encourage therapies for ... Read more